title: [Coronary angioplasty in diabetic patients. Current and future perspectives].
abstract: It has been estimated that 15-25% of patients who undergo percutaneous or surgical coronary angioplasty are diabetics. The indications for coronary revascularization and initial results of the procedure do not differ substantially between patients with diabetes mellitus and non-diabetics. However, the long-term results of both percutaneous and surgical coronary angioplasty are less favorable in diabetics in terms of mortality and the need for new revascularization procedures. The development and widespread use of stents and glycoprotein IIb/IIIa receptor inhibiting drugs have improved the clinical evolution of diabetics treated with angioplasty. Currently available data show that the administration of glycoprotein IIb/IIIa inhibitors to patients undergoing coronary angioplasty is especially useful in diabetics and improves short-term and long-term results, decreasing one-year mortality by 45%. There seem to be indications for the routine use of glycoprotein IIb/IIIa inhibitors in diabetics treated with angioplasty. While the use of stents has improved long-term and short-term results in diabetics, the success rates of angioplasty in diabetics are still lower than in non-diabetics. Diabetes is still an independent predictor of restenosis and long-term events after stenting interventions. Analysis of the studies comparing percutaneous and surgical revascularization in diabetic patients with multivessel disease shows that surgery is superior in terms of long-term mortality and need for new revascularization procedures. Stenting has improved, but not substantially, the results of multivessel angioplasty in diabetics. Therefore, the indications for angioplasty in multivessel diabetics should be evaluated individually. Factors that contribute to the less favorable post-angioplasty evolution of diabetic patients are more rapid progression of atherosclerosis and, especially, a higher rate of restenosis. New angioplasty techniques, such as brachytherapy and drug-eluting stents, are likely to significantly improve the results of percutaneous interventions in diabetics, thus allowing the indications for angioplasty in diabetics to be extended even further in the near future.
authors.affiliation: Instituto de Ciencias del Corazón (ICICOR). Hospital Universitario de Valladolid. Valladolid. España. jalonso@secardiologia.es
authors.forename: Joaquín J
authors.initials: JJ
authors.lastname: Alonso
authors.forename: Juan M
authors.initials: JM
authors.lastname: Durán
authors.forename: Federico
authors.initials: F
authors.lastname: Gimeno
authors.forename: Benigno
authors.initials: B
authors.lastname: Ramos
authors.forename: Ana
authors.initials: A
authors.lastname: Serrador
authors.forename: Francisco
authors.initials: F
authors.lastname: Fernández-Avilés
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000639:trends*; D003327:Coronary Disease / Q000150:complications* / Q000503:physiopathology / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology; D048909:Diabetes Complications; D004562:Electrocardiography; D005544:Forecasting; D006801:Humans; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D015607:Stents
chemical_list: D019039:Platelet Glycoprotein GPIIb-IIIa Complex